anti-EGFR/CD3 bispecific antibody SMET12

{
  "id": "MLC-T-ONC-010604",
  "term": "anti-EGFR/CD3 bispecific antibody SMET12",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody and T-cell engager (TCE) targeting both the tumor-associated antigen (TAA) human epidermal growth factor receptor (EGFR) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-EGFR/CD3 bispecific antibody SMET12 binds to both CD3 expressed on T cells and EGFR expressed on tumor cells. This crosslinks cytotoxic T lymphocytes (CTLs) and EGFR-expressing tumor cells, and activates and redirects CTLs to EGFR-expressing tumor cells. This leads to CTL-mediated killing of EGFR-expressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.",
  "synonyms": [
    "anti-CD3/anti-EGFR bispecific antibody SMET12",
    "anti-EGFR/anti-CD3 bispecific antibody SMET12",
    "EGFR x CD3 bispecific antibody SMET12",
    "EGFR x CD3 T-cell engager SMET12",
    "EGFR x CD3 TCE SMET12"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-egfr-cd3-bispecific-antibody-smet12/"
}